Arrayit achieves technological breakthrough in microarray production Arrayit Corporation.

The advance allows precise printing of as many as 2 highly.4 million microarrays each year with an individual robotic workstation, a significant increase over the business’s current capacity of 640,000 microarrays per device annually. Related StoriesNew results reveal association between colorectal malignancy and melanoma drug treatmentCornell biomedical engineers develop 'super natural killer cells' to destroy malignancy cells in lymph nodesCrucial change in single DNA bottom predisposes children to intense form of cancerArrayit Executive Vice President and Co-Founder Todd Martinsky mentioned, This technological advance represents an engineering tour de pressure that combines our experience in laboratory automation, linear get robotics, micromachining, surface area chemistry and contact printing.With new TB diagnostics and better medications in the offing, we’ve the potential to revolutionize the treating tuberculosis, said William J. Burman, MD, a leading TB professor and expert of medicine at the University of Colorado. When it comes to the TB epidemic, and the risk of drug-resistant TB particularly, this is a time of great need-and also a period of great opportunity. Tuberculosis may be the true number one killer of HIV-contaminated people. Preventing loss of life from TB in HIV-infected sufferers is another clear concern and possible with major scale-up of interventions known to be effective, relating to Burman. Similarly, nearly three years after HIV was known first, Helps remains an incurable, devastating disease, and globally domestically.